Business
Anixa Biosciences to Participate in September Investor Conferences
SAN JOSE, Calif., Aug. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Aug. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (\"Anixa\" or the \"Company\") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in two investor conferences in September. \n\n \n \n \n \n \n \n\n \nH.C. Wainwright 25th Annual Global Investment Conference: Anixa's pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, September 11, 2023, the presentation will also be available on the Company's website at Investor Relations/Events & Presentations.2023 Cantor Global Healthcare Conference: Anixa management is scheduled to present on Thursday, September 28, 2023 at 8:00 AM ET in New York City. The presentation will be broadcast live and archived on the Company's website at Investor Relations/Events & Presentations.Management will be available for one-on-one meetings with interested investors at both conferences.\nAbout Anixa Biosciences, Inc.\nAnixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program that uses a novel type of CAR-T known as chimeric endocrine receptor T-cell (CER-T) technology, and is being developed in collaboration with Moffitt Cancer Center. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against \"retired\" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.\nForward-Looking Statements\nStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements ...